How drug concentrations migrate between cadaver tissues after death — and why sampling site can make or break a forensic toxicology verdict
Every postmortem toxicology result is, implicitly, an attempt to answer a question about the moment before death: what was the drug concentration doing to this person while they were alive? At the instant of death, blood and tissue concentrations reflect ordinary pharmacokinetics — absorption, distribution into tissue compartments governed by lipophilicity and protein binding, and ongoing hepatic or renal clearance. This antemortem distribution is the ground truth that postmortem redistribution (PMR) will subsequently distort.
While alive, a drug's blood concentration is the product of a dynamic balance: absorption from the gut or injection site, distribution into tissue compartments (fat, muscle, liver, brain) according to lipophilicity, plasma protein binding, and continuous clearance by liver metabolism and renal excretion. Blood concentration at any moment is a snapshot of this equilibrium, not a fixed number — it can vary substantially depending on time since last dose, whether the person was in absorption or elimination phase, and organ function.
The volume of distribution (Vd) — a proportionality constant relating total body drug amount to plasma concentration — captures how far a drug partitions out of the vascular compartment into tissue. Vd near total body water (~0.6 L/kg) means the drug stays mostly in blood and extracellular fluid. Vd of 10, 20, or even 50 L/kg means the vast majority of the drug is sequestered in tissue — liver, lung, myocardium, adipose — with only a small fraction circulating in blood at any time. This tissue reservoir is precisely what fuels postmortem redistribution once cellular compartments break down.
Unlike clinical toxicology, where a blood draw happens in a controlled window, forensic sampling occurs after an uncontrolled and often lengthy delay — discovery of the body, transport, refrigeration, and autopsy scheduling can span hours to days. By the time blood is drawn, the tissue architecture that existed at the moment of death has already begun to change. Forensic toxicologists must therefore always ask: does this concentration reflect what killed the person, or partly reflect what happened to their tissues afterward?
This question matters enormously in cases involving high-Vd drugs (tricyclic antidepressants, digoxin, many opioids) where postmortem values from central sites can be several-fold higher than true antemortem levels — sometimes crossing from a "therapeutic" into a apparently "toxic" or "lethal" range purely as an artifact of where and when the sample was drawn.
Death does not stop chemistry — it removes the circulatory and homeostatic systems that kept it organized. Within hours, cell membranes lose ATP-dependent ionic gradients, lysosomes rupture, and autolytic (self-digesting) enzymes break down cellular architecture from the inside out. For a drug that was tightly sequestered inside hepatocytes or pneumocytes during life, this breakdown is the first domino in postmortem redistribution.
In life, cell membranes maintain steep concentration gradients using energy-dependent transporters (Na+/K+-ATPase and drug-specific efflux pumps like P-glycoprotein) that can keep intracellular drug concentrations far higher — or lower — than surrounding plasma. Death eliminates ATP production within minutes as oxygen delivery stops, and these active gradients collapse. What remains is a passive concentration gradient: drug now simply diffuses from high concentration (intracellular, tissue-bound) to low concentration (extracellular fluid, blood) according to Fick's law, unopposed by any active counter-transport.
Lysosomes — membrane-bound organelles packed with acid hydrolases (proteases, lipases, nucleases) — are particularly important. Their membranes are among the first to fail, releasing digestive enzymes into the cytoplasm. This autolysis breaks down the very tissue matrix (liver parenchyma, lung interstitium) that was binding and sequestering the drug, physically liberating it into the surrounding tissue fluid and, subsequently, into adjacent blood vessels and body cavities.
As autolysis proceeds alongside bacterial putrefaction (translocation of gut flora through a now-permeable bowel wall), several additional chemical changes favor drug release and altered measurement:
• pH drift: postmortem tissue typically becomes more acidic initially (anaerobic glycolysis, lactic acid accumulation) then can shift alkaline with putrefaction (ammonia production from protein breakdown) — pH changes alter the ionized/non-ionized fraction of weak base and weak acid drugs, changing membrane permeability and apparent binding • Protein denaturation: plasma and tissue proteins that bound drug (albumin, α1-acid glycoprotein) degrade, releasing previously protein-bound (and therefore "trapped") drug into the free, diffusible pool • Hemolysis: red blood cell breakdown releases intracellular contents and can dilute or concentrate certain analytes measured in "blood," complicating comparison across specimens • Vascular wall permeability increases, so once drug reaches a blood vessel adjacent to a reservoir organ, it can passively cross into the vessel lumen even without any residual circulation to carry it there — diffusion alone suffices.
Postmortem redistribution is not uniform across the body — it is fundamentally a geographic phenomenon. Drug-laden reservoirs (the liver, with its large blood volume and high drug-binding capacity, and the lungs, which trap and concentrate many basic lipophilic drugs) sit in direct anatomical contact with the heart and great vessels. Diffusion happens locally, along the shortest path and steepest gradient — which is exactly why the central cardiac blood pool is affected dramatically while blood drawn from the femoral vein, far from these reservoirs, changes comparatively little.
Forensic toxicologists quantify site-dependent redistribution using the central:peripheral (C/P) ratio — cardiac (or other central) blood concentration divided by peripheral (typically femoral) blood concentration drawn at the same autopsy:
C/P = [drug]cardiac / [drug]peripheral
A C/P ratio near 1.0 suggests minimal redistribution — the drug's concentration was probably similar at time of death and is a reasonably reliable indicator of antemortem exposure. A C/P ratio substantially greater than 1 (commonly using thresholds around 1.5–2 as a flag, per criteria popularized by Pounder and Jones in the late 1980s–1990s) signals that significant postmortem movement has occurred, and that the cardiac (or liver) value likely overestimates the true antemortem concentration.
Digoxin is a textbook example: a cardiac glycoside with high myocardial and hepatic affinity and Vd around 5–7 L/kg, it reliably shows C/P ratios of roughly 2–3 in postmortem cases, a pattern so consistent it is taught as a canonical PMR marker in forensic pathology training. Tricyclic antidepressants (e.g., amitriptyline, imipramine) — highly lipophilic weak bases with Vd often 10–20 L/kg or more — can show C/P ratios exceeding 2 and, in some reported cases, ratios above 5–10 at longer postmortem intervals.
The heart sits in direct venous continuity with two of the body's largest drug reservoirs:
• Hepatic veins drain the liver — often the organ with the single highest tissue drug concentration, given its role in first-pass metabolism and its large blood flow and binding capacity — directly into the inferior vena cava, which empties into the right atrium • Pulmonary veins drain the lungs — which avidly sequester many basic lipophilic drugs (opioids, antidepressants, antihistamines) through ion trapping and extensive tissue binding — directly into the left atrium
Both pathways feed drug-enriched blood directly into the chambers of the heart with essentially no dilution barrier once circulation has stopped and diffusion becomes the only transport mechanism. Blood pooling passively in the right and left ventricles after death sits in immediate contact with myocardial tissue and receives this reservoir efflux continuously as PMI increases.
The femoral vein, by contrast, is anatomically remote from both reservoirs — separated by the length of the pelvis and thigh, with no major reservoir organ draining directly into it. Diffusion distances are much greater and concentration gradients much shallower, so femoral blood concentration changes far more slowly and modestly with time, making it a much closer proxy for the antemortem value.
Postmortem redistribution is not an on/off phenomenon — it is a time-dependent diffusion process that grows with post-mortem interval (PMI) and is strongly modulated by the drug's own pharmacokinetic properties, above all its volume of distribution. Understanding this relationship lets toxicologists gauge, case by case, how much weight to place on a given concentration.
Because postmortem redistribution is driven by passive diffusion down a concentration gradient once cellular and vascular barriers degrade, its magnitude behaves qualitatively like a diffusion-limited process approaching equilibrium: rapid initial change followed by a plateau as the gradient dissipates. Empirically, many studies report measurable C/P shifts beginning within a few hours of death, increasing over roughly the first 24–48 hours, after which further changes are smaller as local gradients equilibrate (though continued putrefaction can introduce additional, less predictable changes at very long PMIs).
This time course means that PMI is one of the single most important case variables to record and factor into interpretation — the same drug at the same true antemortem concentration can show a very different (and rising) C/P ratio depending on how many hours or days elapsed between death and blood sampling at autopsy. Refrigeration of the body slows autolysis and diffusion (lower temperature reduces both enzyme activity and diffusion coefficients), which is one reason prompt refrigeration and earlier autopsy are recommended to limit PMR magnitude.
Vd is, in effect, a proxy for how much drug is sitting in tissue outside the vascular compartment — the size of the reservoir available to diffuse back into central blood after death. Drugs with large Vd (highly lipophilic, extensively tissue-bound, often weak bases that accumulate in acidic lysosomal/mitochondrial compartments via ion trapping) have enormous tissue stores relative to what circulates in blood, so even a small fractional release from that store produces a large relative change in the (much smaller) central blood pool. Drugs with Vd close to total body water (ethanol ~0.6 L/kg, many polar/ionized drugs) have little tissue reservoir to draw from, so their blood concentrations are comparatively stable regardless of PMI — which is precisely why ethanol is considered relatively PMR-resistant and femoral versus cardiac ethanol values are usually similar.
As a rough empirical rule discussed in forensic toxicology literature (echoing work following Pounder and colleagues), drugs with Vd greater than roughly 3–4 L/kg should be considered at meaningfully elevated risk for significant PMR, and any interpretation of concentration for such drugs should explicitly account for sampling site and PMI rather than relying on a single cardiac or liver value.
Because both PMI and Vd independently amplify redistribution, the highest-risk interpretive scenario is a high-Vd drug (TCA, digoxin, many opioids) combined with a long PMI before autopsy — precisely the combination in which cardiac blood concentration can most seriously overstate true antemortem exposure.
The practical payoff of understanding postmortem redistribution is a sampling and interpretation protocol that prevents a diffusion artifact from being misread as evidence of lethal overdose — or, just as dangerously, from masking a genuinely toxic antemortem exposure. Decades of forensic toxicology practice have converged on a set of best practices built directly around the PMR phenomena described in the preceding stages.
Given everything established about site-dependent redistribution, the forensic toxicology community has adopted peripheral (typically femoral vein) blood as the preferred primary specimen for quantitative drug interpretation, rather than cardiac blood or blood pooled from the chest cavity. Femoral blood is drawn by isolating and clamping (or ligating) the femoral vein in the thigh before disturbing the torso, using a clean, dedicated needle and syringe to avoid cross-contamination from adjacent tissues.
This is not merely a theoretical preference: multiple studies comparing paired cardiac and femoral samples across a range of drugs have repeatedly shown that femoral concentrations correlate better with clinical/therapeutic reference ranges and with reconstructed dose history than cardiac concentrations do, particularly for high-Vd drugs. Liver tissue concentration, while useful as a qualitative confirmation of exposure (and sometimes for drugs poorly detected in blood), is even more subject to redistribution and postmortem artifact than cardiac blood and is generally not used alone for quantitative dose reconstruction.
Best practice calls for drawing blood from at least two sites — commonly cardiac and femoral — specifically so the C/P ratio can be calculated and used as a diagnostic flag rather than relying on a single number. If C/P is close to 1 (roughly under 1.5, though exact cutoffs vary by drug class and are used as heuristics rather than fixed law), the cardiac and femoral values agree and either can be interpreted with reasonable confidence. If C/P is substantially elevated, the toxicologist knows redistribution has likely occurred and should weight the femoral (or, if available, a second peripheral site like subclavian blood) more heavily, and should qualify any interpretation of the cardiac or liver number with an explicit caveat about PMR.
Other specimens are used specifically because they resist PMR: vitreous humor (the gel-like fluid in the eye) is anatomically isolated, avascular, and enclosed by a relatively tight physical barrier, making it comparatively resistant to redistribution and putrefaction artifact — useful for alcohol and some electrolyte/drug interpretation even at longer PMIs. Similarly, sampling multiple peripheral sites (femoral plus subclavian) and comparing them can help identify localized artifacts, such as diffusion from a nearby injection site or aspirated stomach contents, that a single peripheral sample might miss.
The forensic toxicology literature contains numerous cautionary case reports in which failure to account for PMR led to disputed or overturned interpretations:
• Digoxin toxicity cases: postmortem cardiac digoxin concentrations in the "toxic" range have been reported in patients whose femoral (and reconstructed antemortem) levels were within the therapeutic range — cardiac sampling alone risked a false determination of digoxin toxicity as cause of death. • Tricyclic antidepressant fatalities: because TCAs are both frequently implicated in fatal overdose and strongly prone to PMR, cardiac-only sampling has historically contributed to overestimation of the ingested dose in some medicolegal reconstructions, complicating manner-of-death determinations (accidental overdose vs. therapeutic-range death from other causes). • Fentanyl and fentanyl analogs: given extremely high potency, very small absolute concentration shifts from PMR can move a measured value across clinically meaningful thresholds; current forensic guidance emphasizes peripheral sampling and cautious interpretation of any single high-Vd opioid concentration, especially at long PMI.
The consistent lesson across these cases is procedural: always document PMI, always attempt paired central and peripheral sampling, always calculate and report the C/P ratio, and never anchor a cause-of-death determination on a single concentration from a central site without that context.
Modern forensic toxicology guidance treats a single, unqualified drug concentration from cardiac blood or liver — without a companion femoral value, a PMI, and an explicit PMR assessment — as insufficient on its own to support a cause-of-death determination for drugs known to be PMR-prone. The number is only as trustworthy as the site and timing it came from.